Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer

Journal of Cancer Research and Clinical Oncology

Volumn 143, Issue 5, 2017, Pages 861-871

  Li, Yingchun ^a   Wang, Chenyu ^a   Xu, Mengdan ^a   Kong, Cuicui ^a   Qu, Aibing ^a   Zhang, Meng ^a   Zheng, Zhichao ^a   Zhang, Guirong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

CIK immunotherapy; DFS; Gastric cancer; NLR

Indexed keywords

FLUOROURACIL; HEMOGLOBIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DISEASE FREE SURVIVAL; ERYTHROCYTE COUNT; FEMALE; GASTRECTOMY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RADICAL RESECTION; RECEIVER OPERATING CHARACTERISTIC; STOMACH CARCINOMA; SURVIVAL PREDICTION; SURVIVAL RATE; THROMBOCYTE COUNT; TUMOR DIFFERENTIATION; ADOPTIVE IMMUNOTHERAPY; CLINICAL TRIAL; IMMUNOLOGY; LYMPHOCYTE; MULTIMODALITY CANCER THERAPY; NEUTROPHIL; PREOPERATIVE CARE; PROCEDURES; RETROSPECTIVE STUDY; STOMACH NEOPLASMS; TRANSPLANTATION;

COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 85009892205     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-016-2330-1     Document Type: Article

References (44)

1. Auphan-Anezin N, Verdeil G, Grange M, Soudja SM, Wehbe M, Buferne M, Mas A, Schmitt-Verhulst AM (2013) Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells? Pigment Cell Melanoma Res 26(2):167–75
2. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2007) Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67(20):10019–26
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015.CA Cancer J Clin 66(2):115–32
4. Coffelt SB, de Visser KE (2014) Cancer: inflammation lights the way to metastasis. Nature 507(7490):48–9
5. Cole WH, Humphrey L (1985) Need for immunologic stimulators during immunosuppression produced by major cancer surgery. Ann Surg 202(1):9–20
6. De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M (2012) Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer 12(4):264–269
7. Donskov F (2013) Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Semin Cancer Biol 23(3):200–207
8. Gabrilovich D, Pisarev V (2003) Tumor escape from immune response mechanisms and targets of activity. Current Drug Targets 4(7):525–36
9. Goode EF, Smyth EC (2016) Immunotherapy for gastroesophageal cancer. J Clin Med 5(10):pii: E84
10. Grenader T, Waddell T, Peckitt C, Oates J, Starling N, Cunningham D, Bridgewater J (2016) Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. Ann Oncol 27(4):687–692
11. Hattar K, Franz K, Ludwig M et al (2014) Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis. Cancer Immunol Immunother 63(12):1297–1306
12. Huh SJ, Liang S, Sharma A, Dong C, Robertson GP (2010) Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res 70(14):6071–82
13. Hwang SG, Kim KM, Cheong JH, Kim HI, An JY, Hyung WJ, Noh SH (2012) Impact of pretreatment thrombocytosis on blood-borne metastasis and prognosis of gastric cancer. Eur J Surg Oncol 38(7):562–567
14. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T (2002) Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 9(3):287–291
15. Jäkel CE, Vogt A, Gonzalez-Carmona MA, Schmidt-Wolf IG (2014) Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res 2014:897214
16. Joo MK, Park JJ, Chun HJ (2016) Recent updates of precision therapy for gastric cancer: towards optimal tailored management. World J Gastroenterol 22(19):4638–50
17. Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749–59
18. Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 48(2):202–8
19. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjöberg J, Pisa P, Petersson M (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48(7):353–62
20. Kim EY, Lee JW, Yoo HM, Park CH, Song KY (2015) The platelet-to-lymphocyte ratio versus neutrophil-to-lymphocyte ratio: which is better as a prognostic factor in gastric cancer? Ann Surg Oncol 22(13):4363–4370
21. Kowanetz M, Wu X, Lee J et al (2010) Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+granulocytes. Proc Natl Acad Sci USA 107(50):21248–55
22. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003) Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6(4):283–287
23. Lazăr DC, Tăban S, Cornianu M, Faur A, Goldiş A (2016) New advances in targeted gastric cancer treatment. World J Gastroenterol 22(30):6776–99
24. Lee JH, Lee JH, Lim YS et al (2015) Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 148(7):1383–91.e6
25. Li Y, Jin A, Chen S, Song C, Zhang G (2015) Efficacy of adjuvant chemotherapy combined with CIK cell immunotherapy in 130 patients with postoperative colorectal cancer [in Chinese]. J Chin Oncol 21(10):843–847
26. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics. CA Cancer J Clin 66(4):271–89
27. Nagtegaal ID, Marijnen CA, Kranenbarg EK et al (2001) Local and distant recurrences in rectal cancer patients are predicted by the nonspecificimmune response; specific immune response has only a systemic effect–a histopathological and immunohistochemical study. BMC Cancer 1:7
28. Ostrand-Rosenberg S (2008) Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18(1):11–8
29. Pattison CW, Woods KL, Morrison JM (1987) Lymphocytopenia as an independent predictor of early recurrence in breast cancer. Br J Cancer 55(1):75–6
30. Petrie HT, Klassen LW, Kay HD (1985) Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol 134(1):230–4
31. Said N, Theodorescu D (2012) RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment. Oncoimmunology 1(7):1175–1177
32. Satomi A, Murakami S, Ishida K, Mastuki M, Hashimoto T, Sonoda M (1995) Significance of increased neutrophils in patients with advanced colorectal cancer. Acta Oncol 34(1):69–73
33. Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IG (2015) Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 141(5):839–849
34. SchmidtWolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174(1):139–49
35. Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J, Wu C (2012) Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 61(12):2251–2259
36. Slaney CY, Kershaw MH, Darcy PK (2014) Trafficking of T cells into tumors. Cancer Res 74(24):7168–74
37. Stockmann C, Schadendorf D, Klose R, Helfrich I (2014) The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol 4:69
38. Stroncek D, Berlyne D, Fox B et al (2010) Developments in clinical cell therapy. Cytotherapy 12(3):425–8
39. Sun S, Li X, Yu Z, Xu M, Liao Y, Zhang G (2016) The differences of the blood indicators between the healthy people and patients with lung cancer. J Mod Oncol ISSN 1672–4992
40. Takahashi T, Saikawa Y, Kitagawa Y (2013) Gastric cancer: current status of diagnosis and treatment. Cancers (Basel) 5(1):48–63
41. Takahashi R, Mabuchi S, Kawano M et al (2015) Prognostic significance of systemic neutrophil and leukocyte alterations in surgically treated endometrial cancer patients: a monoinstitutional study. Gynecol Oncol 137(1):112–118
42. Wang D, DuBois RN (2015) Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis 36(10):1085–93
43. Wang SC, Chou JF, Strong VE, Brennan MF, Capanu M, Coit DG (2016) Pretreatment neutrophil to lymphocyte ratio independently predicts disease-specific survival in resectable gastroesophageal junction and gastric adenocarcinoma. Ann Surg 263(2):292–297
44. Whiteside TL (2006) The role of immune cells in the tumor microenvironment. Cancer Treat Res 130:103–124